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TO THE EDITOR
The pathophysiological features of
chronic inflammatory skin diseases
such as allergic contact dermatitis and
atopic dermatitis are characterized by
the infiltration of a large number of
inflammatory cells, particularly Th2
lymphocytes (producing IL-13 and/or
IL-4 in acute lesions) and Th1 lympho-
cytes (producing IFN-g in chronic
lesions) (Leung et al., 2004). The pre-
sence of IL-13-positive cells in acute
lesions of atopic dermatitis (Hamid
et al., 1996) and the importance of IL-
13, independent of IL-4 in generation of
Th2 immune response in skin compart-
ment has been described.
In human primary keratinocytes
(KCs), IL-13 interacts with two different
receptors: one is the IL-4 type II
receptor complex (IL-4Ra and IL-
13Ra1) and the other is high-affinity
IL-13Ra2. IL-13Ra1 is expressed on
nearly all cells including KCs except
on T cells and signals via JAK/signal
transducer and activator of transcription
(STAT) pathways (Hershey, 2003). IL-
13Ra2 interacts with IL-13 but not with
IL-4 and has been suggested to function
as a decoy receptor because the cyto-
plasmic region of IL-13Ra2 does not
have a signaling motif or JAK/STAT
binding sequence (Kawakami et al.,
2001). However, it has recently been
suggested that IL-13Ra2 might also be
involved in IL-13 signaling via AP-1
(Fichtner-Feigl et al., 2006). Neverthe-
less, very little is known about the
expression and mechanism regulating
the expression of IL-13Ra1 and IL-
13Ra2 on KCs. With this study, we
examine how cytokines involved in
inflammatory skin diseases can influ-
ence the IL-13 responses of KCs by
modulating the expression of IL-13Ra1
and IL-13Ra2.
To get insight into the cytokine
regulation of IL-13Ra1 expression on
KCs, we analyzed surface expression by
flow cytometry using specific mAbs. In
all experiments, there was a surface
expression of IL-13Ra1 detectable on
KCs (Figure 1a). We used several
cytokines such as transforming growth
factor (TGF)-b1 (0.1–10 ng/ml) and IL-
1b, TNF-a, IFN-g, IL-4, GM-CSF, and IL-
13 at 10 ng/ml to demonstrate the
modulation of IL-13Ra1 on KCs. As
depicted in Figure 1a, TGF-b1 (1 ng/ml)
upregulated the expression of IL-13Ra1
significantly (mean fluorescence inten-
sity7SEM in unstimulated; 10.9371.7
and TGF-b1; 14.7272.4, P¼0.002,
paired t-test, n¼ 7). TGF-b1 at 0.1 and
10 ng/ml concentrations also induced
IL-13Ra1 on KCs significantly (data not
shown). However, IL-1b, TNF-a, GM-
CSF, IL-4, and IFN-g did not show
significant effects on the modulation of
IL-13Ra1 expression (data not shown).
Previously, IFN-g (100 ng/ml) and IL-13
(100 ng/ml) have been described to
upregulate IL-13Ra1 at messenger RNA
level (Wongpiyabovorn et al., 2003). We
could not observe modulation of IL-
Abbreviations: KC, human primary keratinocyte; STAT, signal transducer and activator of transcription;
TGF, transforming growth factor
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13Ra1 surface expression by these cyto-
kines at protein level. On keratinocytes
derived from psoriatic skin, Cancino-
Diaz et al. (2002) have shown the over
expression of IL-13Ra1 at RNA level and
underexpression at protein level.
Interaction of IL-13 and IL-13 Ra1
activates JAK/STAT-6 kinases in various
cell types including HaCaT (David
et al., 2001). We further confirmed the
activation of STAT-6 in KCs (primary
cultured cells) after 15 minutes of IL-13
or IL-4 stimulation as detected by
phosphorylation of STAT-6 in Western
blotting (Figure 1b).
To investigate the effect of IL-13 on
CCL5 expression, KCs were stimulated
with IL-13 (1-50 ng/ml) and TGF-b1
(1 ng/ml) at several time points
(24–96 hours). As depicted in Figure
1c, neither IL-13 at low concentration
(1–10 ng/ml) nor TGF-b1 (1 ng/ml) alone
could significantly induce CCL5 pro-
duction after 72 hours. Induction of
CCL5 in KCs by IL-13 could only be
observed at 50 ng/ml concentration.
Although the effect for IL-13 was
significant, the increase in CCL5 pro-
duction seems not biologically relevant
(unstimulated 344.7 pg/ml730.4 and
IL-13 50 ng/ml: 412.7 pg/ml7SEM
25.5, n¼ 9). However, TGF-b1 (1 ng/
ml) and IL-13 (50 ng/ml) in combination
showed a strong and synergistic effect
on CCL5 induction after 72 hours of
KCs stimulation (Figure 1c). Time ki-
netic experiments showed that TGF-b1
and IL-13 in combination induced
CCL5 production after 48 hours, how-
ever, the induction reached a maximum
at 72 hours of stimulation (Figure 1d).
Incubation time of 96 hours showed no
further increase. Previously, Albanesi
et al. (Albanesi et al., 2001) have also
described the late induction of CCL5
(mRNA) in KCs stimulated with super-
natant derived from Th2 cells. CCL5 is a
strong chemoattractant for eosinophils,
T lymphocytes and monocytes. It is
noteworthy that in a skin inflammatory
situation with known expression of IL-
13 (Hamid et al., 1996), TGF-b1 may
not act as an anti-inflammatory medi-
ator but acts in concert with IL-13 to
recruit inflammatory cells into the
upper layers of the skin (Purwar et al.,
2006).
To investigate the presence and
cytokine regulation of IL-13Ra2, KCs
were subjected to a Th1 cytokine (IFN-
g, 10 ng/ml), a Th2 cytokine (IL-13,
50 ng/ml) and TNF-a (10 ng/ml) alone,
or in combination with Th1 and Th2
cytokine(s) for 24 hours. As depicted in
Figure 2a, unstimulated KCs express
low level of IL-13Ra2, however, IFN-g
could upregulate the IL-13Ra2 as ana-
lyzed by flow cytometry using specific
mAb. TNF-a alone had no strong effect
on IL-13Ra2 expression; but in combi-
nation with IL-13, it markedly upregu-
lated the receptor expression (Figure
2a). IFN-g has been demonstrated to
inhibit the development of Th2 immune
responses in a variety of experimental
systems (Ford et al., 2001). Upregula-
tion of IL-13Ra2 by IFN-g might con-
tribute to the counter-regulatory control
of IFN-g on IL-13-induced cellular
responses.
To confirm that IL-13, TNFa, and
IFN-g have direct effect on IL-13Ra2
expression, we evaluated the induction
of IL-13Ra2 by quantitative real-time
RT-PCR. A very low level of IL-13Ra2
messenger RNA was detected in un-
stimulated cells and IFN-g strongly
upregulated IL-13Ra2 messenger RNA
(not shown) and surface expression
(Figure 2a). IL-13 alone and in combi-
nation with TNF-a showed synergistic
effect in induction of the IL-13Ra2
messenger RNA (Figure 2b) and surface
70
60
50
40
30
20
10
0
Isotype
NS TGF-1
100 101 102 103FL1-H
IL-13R1
 IL-13+ 
TGF-1
TGF-1
Co
un
ts
700
750
500
250CC
L5
 (p
g/m
l)
0
600
500
400
300
200
CC
L5
 (p
g/m
l)
NS
(50 ng/ml) (1 ng/ml)
IL-13
∗∗
∗∗∗
NS IL-13 IL-4
Phospho-STAT6
TGF-1 (1 ng/ml)
IL-13      (50 ng/ml)
Time      (hours)
–
–
+
+
+
+
+
+
24 48 72
∗
a c
b d
Figure 1. Human KCs express functional IL-13Ra1. KCs were isolated as described previously (Purwar et al., 2006). (a) KCs were stimulated with indicated
cytokine(s) for 24 hours and IL-13Ra1 expression was determined by flow cytometry using an IL-13Ra1 mAb. Representative histogram is shown from six
different experiments with cells from different donors. (b) KCs were stimulated with IL-13 (50 ng/ml) or IL-4 (50 ng/ml) for 15 minutes. Cells were lysed and
phospho-STAT6 was detected by Western blotting. (c and d) KCs were stimulated with TGF-b1 (1 ng/ml) and IL-13 (50 ng/ml) (24–72 hours; Figure 1c: 72 hours).
CCL5 was measured in cell-free supernatants by CCL5-specific ELISA according to the manufacturer’s instructions (Duoset, RnD systems). Mean7SEM is given.
**Po0.02 and ***Po0.01 (compared to NS, not stimulated).
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expression (Figure 2a). The induction of
IL-13Ra2 may be functionally important
as IL-13 induced TNF-a induction was
abrogated by IFN-g given 30 minutes
before IL-13 to cultured KCs (Figure 2c).
We could observe the same trend for IL-
1R type II (not shown). However, we
could not exclude that the reduced
secretion of IL-1R type II and TNF-a
by IFN-g might be due to other modes
of action besides upregulation of IL-
13Ra2 (e.g., upregulation of SOCS).
Nevertheless, it is important to note
that high affinity of IL-13Ra2 towards
IL-13 as compared to IL-13Ra1 may
reduce the extent of IL-13 effects in skin
inflammation. Therefore the regulation
of IL-13Ra2 by IFN-g and IL-13 might
contribute to the IL-13 effects in vivo.
Further studies will be required to
define the exact role of IL-13Ra2 on
IL-13-mediated effects in Th2-domi-
nated disorders.
With this study, we have delineated
the coordinated influence of cytokines
in regulating the IL-13Rs on KCs, which
might have impact in fine tuning the IL-
13-mediated skin inflammation.
Furthermore, this study demonstrates a
synergistic role of IL-13 and TGF-b1 in
induction of CCL5 that propose a
potential role of IL-13 in the skin
inflammation by means of facilitating
the migration of inflammatory cells in
the epidermal compartment.
The study was approved by the
ethics committe of the Hannover Med-
ical School and was conducted accord-
ing to the Declaration of Helsinki
Principles. All participants gave their
written informed consent.
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Figure 2. Expression and cytokine regulation of IL-13Ra2 in KCs. KCs were stimulated with IL-13 (50 ng/ml), IFN-g (10 ng/ml), TNF-a (10 ng/ml) for 24 hours
(protein), or 6 hours (RNA). (a) Representative dot-plots are shown from five different experiments with cells from different donors. The values shown in dot-plots
correspond to percentage of IL-13Ra2-positive cells. (b) Total RNA was isolated and complementary DNA was synthesized. Data in bar graphs are shown as
percentage induction of IL-13Ra2 messenger RNA after indicated cytokine stimulation. (c) Supernatant were collected 24 hours after stimulation with the
indicated cytokines. TNF-a was determined by ELISA (DuoSet, R&D Systems, Wiesbaden, Germany). Only those experiments were included into the analysis
where IL-13 alone but not IFN-g alone induced TNF-a (n¼ 3).
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